Polyanalgesic consensus conference 2012: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an interdisciplinary expert panel

Neuromodulation

Volumn 15, Issue 5, 2012, Pages 436-466

  Deer, Timothy R ^a   Prager, Joshua ^b   Levy, Robert ^c   Rathmell, James ^d   Buchser, Eric ^e   Burton, Allen ^f   Caraway, David ^g   Cousins, Michael ^h   De Andrés, José ⁱ   Diwan, Sudhir ^j   Erdek, Michael ^k   Grigsby, Eric ^l   Huntoon, Marc ^m   Jacobs, Marilyn S ^b   Kim, Philip ⁿ   Kumar, Krishna ^o   Leong, Michael ^p   Liem, Liong ^q   Ii, Gladstone C McDowell ^r   Panchal, Sunil ^s   Rauck, Richard ^t   Saulino, Michael ^u   Todd Sitzman, B ^v   Staats, Peter ^w   Stanton Hicks, Michael ^x   Stearns, Lisa ^y   Wallace, Mark ^z   Dean Willis, K ^aa   Witt, William ^ab   Yaksh, Tony ^z   Mekhail, Nagy ^x   more..

^a Center for Pain Relief   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f Houston Pain Associates LLC   (United States)

^g Center for Pain Relief LLC   (United States)

^h ROYAL NORTH SHORE HOSPITAL   (Australia)

ⁱ UNIVERSITY OF VALENCIA   (Spain)

^j STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Napa Pain Institute and Neurovations Clinical Research and Education   (United States)

^m VANDERBILT UNIVERSITY   (United States)

ⁿ CHRISTIANA HOSPITAL   (United States)

^o UNIVERSITY OF SASKATCHEWAN   (Canada)

^p STANFORD UNIVERSITY   (United States)

^q ST ANTONIUS HOSPITAL   (Netherlands)

^r Integrated Pain Solutions   (United States)

^s National Institute of Pain   (United States)

^t WAKE FOREST SCHOOL OF MEDICINE   (United States)

^u THOMAS JEFFERSON UNIVERSITY   (United States)

^v PLLC   (United States)

^w Premier Pain Management Centers   (United States)

^x LERNER RESEARCH INSTITUTE   (United States)

^y Center for Pain and Supportive Care   (United States)

^z UNIVERSITY OF CALIFORNIA   (United States)

^aa Alabama Pain Center Huntsville   (United States)

^ab UNIVERSITY OF KENTUCKY   (United States)

more..

Author keywords

Chronic pain; consensus; intrathecal

Indexed keywords

ADENOSINE; BACLOFEN; BUPIVACAINE; CLONIDINE; DEXMEDETOMIDINE; DROPERIDOL; FENTANYL; GABAPENTIN; HYDROMORPHONE; KETAMINE; KETOROLAC; LEVOBUPIVACAINE; LIDOCAINE; METHADONE; MIDAZOLAM; MORPHINE; MORPHINE SULFATE; MOXONIDINE; NEOSTIGMINE; OCTREOTIDE; OMEGA CONOTOXIN MVIIA; OPIATE; PETHIDINE; ROPIVACAINE; SUFENTANIL; TETRACAINE;

ADD ON THERAPY; ALGORITHM; AMYOTROPHIC LATERAL SCLEROSIS; ANALGESIA; ARTICLE; CANCER PAIN; CATHETER COMPLICATION; CEREBRAL PALSY; CEREBROSPINAL FLUID FLOW; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONSENSUS DEVELOPMENT; DRUG DELIVERY SYSTEM; DRUG OVERDOSE; DRUG SAFETY; EXPERIENCE; GRANULOMA; HEALTH CARE ACCESS; HUMAN; HYPERALGESIA; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFORMATION RETRIEVAL; LIPID SOLUBILITY; MEDICARE; NEUROPATHIC PAIN; NEUROTOXICITY; NOCICEPTIVE PAIN; NONHUMAN; PARTITION COEFFICIENT; PATIENT CARE; PATIENT MONITORING; PERIPHERAL EDEMA; POSTDURAL PUNCTURE HEADACHE; PSYCHOLOGICAL ASPECT; RESPIRATION DEPRESSION; SCOLIOSIS; SLEEP DISORDERED BREATHING; SPASTICITY; SPINAL CORD INJURY; STIFF MAN SYNDROME; WITHDRAWAL SYNDROME;

EID: 84867576279     PISSN: 10947159     EISSN: 15251403     Source Type: Journal    
DOI: 10.1111/j.1525-1403.2012.00476.x     Document Type: Article

References (277)

1. Bennett G, Burchiel K, Buchser E, et al,. Clinical guidelines for intraspinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000. J Pain Symptom Manage 2000; 20: S37-S43.
2. Hassenbusch SJ, Portenoy RK, Cousins M, et al,. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-report of an expert panel. J Pain Symptom Manage 2004; 27: 540-563.
3. Deer T, Krames ES, Hassenbusch SJ, et al,. Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007; 10: 300-328.
4. Allen JW, Horais KA, Tozier NA, Yaksh TL,. Opiate pharmacology of intrathecal granulomas. Anesthesiology 2006; 105: 590-598.
5. Fukushima S, Takenami T, Yagishita S, Nara Y, Hoka S, Okamoto H,. Neurotoxicity of intrathecally administered fentanyl in a rat spinal model. Pain Med 2011; 12: 717-725.
6. Hocking G, Wildsmith JA,. Intrathecal drug spread. Br J Anaesth 2004; 93: 568-578.
7. Degrell I, Nagy E,. Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid. Biol Psychiatry 1990; 27: 891-896.
8. Weisner B, Bernhardt W,. Protein fractions of lumbar, cisternal, and ventricular cerebrospinal fluid. Separate areas of reference. J Neurol Sci 1978; 37: 205-214.
9. Greitz D, Franck A, Nordell B,. On the pulsatile nature of intracranial and spinal CSF-circulation demonstrated by MR imaging. Acta Radiol 1993; 34: 321-328.
10. Enzmann DR, Pelc NJ,. Normal flow patterns of intracranial and spinal cerebrospinal fluid defined with phase-contrast cine MR imaging. Radiology 1991; 178: 467-474.
11. Greitz D,. Cerebrospinal fluid circulation and associated intracranial dynamics. A radiologic investigation using MR imaging and radionuclide cisternography. Acta Radiol Suppl 1993; 386: 1-23.
12. Henry-Feugeas MC, Idy-Peretti I, Blanchet B, Hassine D, Zannoli G, Schouman-Claeys E,. Temporal and spatial assessment of normal cerebrospinal fluid dynamics with MR imaging. Magn Reson Imaging 1993; 11: 1107-1118.
13. Ummenhofer WC, Arends RH, Shen DD, Bernards CM,. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology 2000; 92: 739-753.
14. Bernards CM, Shen DD, Sterling ES, et al,. Epidural, cerebrospinal fluid, and plasma pharmacokinetics of epidural opioids (part 1): differences among opioids. Anesthesiology 2003; 99: 455-465.
15. Flack SH, Anderson CM, Bernards C,. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg 2011; 112: 460-464.
16. Flack SH, Bernards CM,. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs. Anesthesiology 2010; 112: 165-173.
17. Bernards CM,. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 2006; 105: 169-178.
18. Nelissen RM,. Fluid mechanics of intrathecal drug delivery. Lausanne: Federal Institute of Technology, 2008.
19. Shafer SL, Shafer A,. In:, Yaksh TL, ed. Spinal pharmacokinetics, spinal drug delivery. Amsterdam: Elsevier, 1999: 271-295.
20. Buchser E, Durrer A, Chédel D, Mustaki JP,. Efficacy of intrathecal bupivacaine: how important is the flow rate? Pain Med 2004; 5: 248-252.
21. van der Plas AA, Marinus J, Eldabe S, Buchser E, van Hilten JJ,. The lack of efficacy of different infusion rates of intrathecal baclofen in complex regional pain syndrome: a randomized, double-blind, crossover study. Pain Med 2011; 12: 459-465.
22. Perruchoud C, Eldabe S, Durrer A, et al,. Effects of flow rate modifications on reported analgesia and quality of life in chronic pain patients treated with continuous intratecal drug therapy. Pain Med 2011; 12: 571-576.
23. Nelson KE, Houle TT, Eisenach JC,. Blood pressure, but not cerebrospinal fluid fentanyl concentration, predicts duration of labor analgesia from spinal fentanyl. Anesthesiology 2010; 112: 174-180.
24. Dominguez E, Sahinler B, Bassam D, et al,. Predictive value of intrathecal narcotic trials for long-term therapy with implantable drug administration systems in chronic non-cancer pain patients. Pain Pract 2002; 2: 315-325.
25. British Pain Society. Intrathecal drug delivery for the management of pain and spasticity in adults; recommendations for best clinical practice. 2008. http://www.britishpainsociety.org/book-ittd-main.pdf. Accessed July 19, 2011.
26. Walker J, Farney R, Rhondeau S, et al,. Chronic opoid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007; 3: 455-461.
27. Mangram A, Horan T, Pearson M, et al,. Guideline for prevention for surgical site infection 1999. Infect Control Hosp Epidemiol 1999; 20: 247-278.
28. Horlocker T, Wedel D, Rowlingson J, et al,. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American society of regional anesthesia and pain medicine evidence-based guidelines (third edition). Reg Anesth Pain Med 2010; 35: 64-101.
29. Coffey R, Owens M, Broste S, et al,. Mortality associated with the implantation and management of intrathecal opoid drug infusion systems to treat noncancer pain. Anesthesiology 2009; 111: 881-891.
30. Angst M, Clark D,. Opoid-induced hyperalgesia: a qualitative systematic review. Ansesthesiology 2006; 104: 570-587.
31. Deer T, Smith H, Cousins M, et al,. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician 2010; 13: E175-E213.
32. Punjabi NM,. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008; 5: 136-143.
33. Paice JA, Penn RD, Shott S,. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 1996; 11: 71-80.
34. Benyamin R, Trescot A, Datta S, et al,. Opoid complications and side effects. Pain Physician 2008; 11: 105-120.
35. Medtronic. 2008 letter. Updated information-Inflammatory mass (granuloma) at or near the distal tip of intrathecal catheters.
36. Deer TR, Raso LJ, Coffey RJ, Allen JW,. Intrathecal baclofen and catheter tip inflammatory mass lesions (granulomas): a revaluation of case reports and imaging findings in light of experimental, clinicalopathological, and radiological evidence. Pain Med 2008; 9: 391-395.
37. Murphy P, Skouvaklis D, Amadeo R, Haberman C, Brazier D, Cousins M,. Intrathecal catheter granuloma associated with isolated baclofen infusion. Anesth Analg 2006; 102: 848-852.
38. Deer T, Krames E, Hassenbusch S, Burton A, Caraway D, Dupen S, Eisenach J, et al,. Management of IT catheter tip inflammatory masses: an updated 2007 consensus statement from an expert panel. Neuromodulation 2008; 11: 77-91.
39. Candido KD, Stevens RA,. Post-dural puncture headache: pathophysiology, prevention and treatment. Best Pract Res Clin Anaesthesiol 2003; 17: 451-469.
40. Pohl JZ,. Uber das N-allylnorcodein, einin antagonisten des morphins. Z Exp Pathol Therap 1915; 17: 370-382.
41. Isbell H, Fraser HF,. Addiction to analgesics and barbiturates. J Pharmacol Exp Ther 1950; 99: 355-397.
42. Lasagna L, Beecher HK,. The analgesic effectiveness of codeine and meperidine (Demerol). J Pharmacol Exp Ther 1954; 112: 306-311.
43. Wu KM, Martin MR, Kamerling SG, Wettstein JG,. Possible medullary kappa hyperalgesic mechanism. I. A new potential role for endogenous opioid peptides in pain perception. Life Sci 1983; 33: 1831-1838.
44. Gardell LR, Wang R, Burgess SE, et al,. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002; 22: 6747-6755.
45. Coffey RJ, Owens ML, Broste SK, et al,. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain. Pain Med 2010; 11: 1001-1009.
46. Maier C, Gockel HH, Gruhn K, Krumova EK, Edel MA,. Increased risk of suicide under intrathecal ziconotide treatment?-A warning. Pain 2011; 152: 235-237.
47. Thompson JC, Dunbar E, Laye RR,. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Pain Physician 2006; 9: 147-152.
48. Azur Pharma, Inc. Prialt [package insert]. Philadelphia, PA: Azur Pharma Inc., 2010.
49. Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G,. Ziconotide for treatment of severe chronic pain. Lancet 2010; 375: 1569-1577.
50. Gofeld M, McQueen CK,. Ultrasound-guided intrathecal pump access and prevention of the pocket fill. Pain Med 2011; 12: 607-611.
51. Levy LM, Chiro G,. MR phase imaging and cerebrospinal fluid flow in the head and spine. Neuroradiology 1990; 32: 399-406.
52. Enzmann DR, Pelc NJ,. Cerebrospinal fluid flow measured by phase-contrast cine MR. Am J Neuroradiol 1993; 14: 1301-1307.
53. Johnston M,. The importance of lymphatics in cerebrospinal fluid transport. Lymphat Res Biol 2003; 1: 41-45.
54. Hassenbusch SJ, Paice JA, Patt RB, Bedder MD, Bell GK,. Clinical realities and economic considerations: economics of intrathecal therapy. J Pain Symptom Manage 1997; 14 (Suppl.): S36-S48.
55. Deer TR, Smith HS, Burton AW, et al,. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician 2011; 14: E283-E312.
56. Fukazawa Y, Maeda T, Kiguchi N, Tohya K, Kimura M, Kishioka S,. Activation of spinal cholecystokinin and neurokinin-1 receptors is associated with the attenuation of intrathecal morphine analgesia following electroacupuncture stimulation in rats. J Pharmacol Sci 2007; 104: 159-166.
57. Kolesnikov Y, El-Maarouf A, Rutishauser U, Pasternak G,. Reorganization of dorsal root ganglion neurons following chronic sciatic nerve constriction injury: correlation with morphine and lidocaine analgesia. Eur J Pharmacol 2007; 568: 124-133.
58. Liu NJ, von Gizycki H, Gintzler AR,. Sexually dimorphic recruitment of spinal opioid analgesic pathways by the spinal application of morphine. J Pharmacol Exp Ther 2007; 322: 654-660.
59. Shui HA, Ho ST, Wang JJ, et al,. Proteomic analysis of spinal protein expression in rats exposed to repeated intrathecal morphine injection. Proteomics 2007; 7: 796-803.
60. Satarian L, Javan M, Fathollahi Y,. Epinephrine inhibits analgesic tolerance to intrathecal administrated morphine and increases the expression of calcium-calmodulin-dependent protein kinase IIalpha. Neurosci Lett 2008; 430: 213-217.
61. Fisher A, Dickenson A,. Morphine efficacy in a rat model of osteoarthritis-spinal and supraspinal interactions with descending noradrenergic mechanisms [abstract]. Eur J Pain 2009; 13 (Suppl. 1): S112.
62. Chen P, Wang D, Li M, Zhang Y, Quirion R, Hong Y,. Modulation of sensory neuron-specific receptors in the development of morphine tolerance and its neurochemical mechanisms. J Neurosci Res 2010; 88: 2952-2963.
63. González-Rodríguez S, Hidalgo A, Baamonde A, Menéndez L,. Involvement of Gi/o proteins and GIRK channels in the potentiation of morphine-induced spinal analgesia in acutely inflamed mice. Naunyn Schmiedebergs Arch Pharmacol 2010; 381: 59-71.
64. Hajializadeh Z, Esmaeili-Mahani S, Sheibani V, Kaeidi A, Atapour M, Abbasnejad M,. Changes in the gene expression of specific G-protein subunits correlate with morphine insensitivity in streptozotocin-induced diabetic rats. Neuropeptides 2010; 44: 299-304.
65. Hutchinson MR, Zhang Y, Shridhar M, et al,. Evidence that opioids may have Toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010; 24: 83-95.
66. Hutchinson MR, Lewis SS, Coats BD, et al,. Possible involvement of Toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience 2010; 167: 880-893.
67. Holtman JR Jr, Crooks PA, Johnson-Hardy J, Wala EP,. Antinociceptive effects and toxicity of morphine-6-O-sulfate sodium salt in rat models of pain. Eur J Pharmacol 2010; 648: 87-94.
68. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT,. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007; 132: 289-300.
69. Holtman JR Jr, Crooks PA, Johnson-Hardy J, Wala EP,. Interaction between morphine and norketamine enantiomers in rodent models of nociception. Pharmacol Biochem Behav 2008; 90: 769-777.
70. Kosson D, Klinowiecka A, Kosson P, et al,. Intrathecal antinociceptive interaction between the NMDA antagonist ketamine and the opioids, morphine and biphalin. Eur J Pain 2008; 12: 611-616.
71. He ZH, Guo QL, Zou WY, Huang CS,. Intrathecal injection of ketamine and clonidine for chronic neuropathic pain model in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2007; 32: 702-705.
72. Makuch W, Starowicz K, Przewlocka B,. Effects of selective inhibitors of neuronal nitric oxide synthase on morphine and endomorphin-1-induced analgesia in acute and neuropathic pain [abstract]. Eur J Pain 2009; 13 (Suppl. 1): S77.
73. Nishiyama T,. Antinociceptive interaction between intrathecally administered morphine and epibatidine in rats. Eur J Anaesthesiol 2009; 26 (Suppl. 45): 190.
74. Pettersen VL, Zapata-Sudo G, Raimundo JM, Trachez MM, Sudo RT,. The synergistic interaction between morphine and maprotiline after intrathecal injection in rats. Anesth Analg 2009; 109: 1312-1317.
75. Tai YH, Tsai RY, Lin SL, et al,. Amitriptyline suppresses neuroinflammation-dependent interleukin-10-p38 mitogen-activated protein kinase-heme oxygenase-1 signaling pathway in chronic morphine-infused rats. Anesthesiology 2009; 110: 1379-1389.
76. Lin SL, Tsai RY, Shen CH, et al,. Co-administration of ultra-low dose naloxone attenuates morphine tolerance in rats via attenuation of NMDA receptor neurotransmission and suppression of neuroinflammation in the spinal cords. Pharmacol Biochem Behav 2010; 96: 236-245.
77. Shen CH, Tsai RY, Shih MS, et al,. Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Anesth Analg 2011; 112: 454-459.
78. Haroutiunian S, Yifrah I, Hoffman A,. Comparison of intravenous, epidural and intrathecal administration of methadone in a rat model [abstract]. J Pain 2009; 10 (Suppl. 1): S54.
79. Shields D, Montenegro R,. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administartion. Neuromodulation 2007; 10 (Suppl. 1): 6-11.
80. Shields DE, Aclan J, Szatkowski A,. Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. Int J Pharm Compounding 2008; 12: 463-466.
81. Zin CS, Nissen LM, O'Callaghan JP, Moore BJ, Smith MT,. Preliminary study of the plasma and cerebrospinal fluid concentrations of IL-6 and IL-10 in patients with chronic pain receiving intrathecal opioid infusions by chronically implanted pump for pain management. Pain Med 2010; 11: 550-561.
82. Yaksh TL, Horais KA, Tozier NA, et al,. Chronically infused intrathecal morphine in dogs. Anesthesiology 2003; 99: 174-187.
83. Gradert TL, Baze WB, Satterfield WC, Hildebrand KR, Johansen MJ, Hassenbusch SJ,. Safety of chronic intrathecal morphine infusion in a sheep model. Anesthesiology 2003; 99: 188-198.
84. Johansen MJ, Satterfield WC, Baze WB, Hildebrand KR, Gradert TL, Hassenbusch SJ,. Continuous intrathecal infusion of hydromorphone: safety in the sheep model and clinical implications. Pain Med 2004; 5: 14-25.
85. Atli A, Theodore BR, Turk DC, Loeser JD,. Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. Pain Med 2010; 11: 1010-1016.
86. Berg A, Barsa J, Deer T, et al,. Efficacy of morphine sulfate infusion via the Prometraâ Intrathecal Infusion Pump. A prospective multicenter evaluation: PB238 [abstract]. Pain Pract 2009; 9 (Suppl. 1): 159.
87. Kongkam P, Wagner DL, Sherman S, et al,. Intrathecal narcotic infusion pumps for intractable pain of chronic pancreatitis: a pilot series. Am J Gastroenterol 2009; 104: 1249-1255.
88. Shaladi A, Saltari MR, Piva B, et al,. Continuous intrathecal morphine infusion in patients with vertebral fractures due to osteoporosis. Clin J Pain 2007; 23: 511-517.
89. Saltari MR, Shaladi A, Piva B, et al,. The management of pain from collapse of osteoporotic vertebrae with continuous intrathecal morphine infusion. Neuromodulation 2007; 10: 167-176.
90. Reig E, Abejon D,. Continuous morphine infusion: a retrospective study of efficacy, safety, and demographic variables. Neuromodulation 2009; 12: 122-129.
91. Mercadante S, Intravaia G, Villari P, et al,. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 2007; 23: 793-798.
92. Raffaeli W, Righetti D, Caminiti A, et al,. Implantable intrathecal pumps for the treatment of noncancer chronic pain in the elderly population: drug dose and clinical efficacy. Neuromodulation 2008; 11: 33-39.
93. Webster LR, Fakata KL, Charapata S, Fisher R, MineHart M,. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 2008; 9: 282-290.
94. Shields DC, Palma C, Khoo LT, Ferrante FM,. Extramedullary intrathecal catheter granuloma adherent to the conus medullaris presenting as cauda equina syndrome. Anesthesiology 2005; 102: 1059-1061.
95. Campana G, Sarti D, Spampinato S, Raffaeli W,. Long-term intrathecal morphine and bupivacaine upregulate MOR gene expression in lymphocytes. Int Immunopharmacol 2010; 10: 1149-1152.
96. Ruan X, Couch JP, Liu H, Shah RV, Wang F, Chiravuri S,. Respiratory failure following delayed intrathecal morphine pump refill: a valuable, but costly lesson. Pain Physician 2010; 13: 337-341.
97. Ruan X, Tadia R, Couch JP, Ruan J, Chiravuri S,. Severe peripheral edema during an outpatient continuous epidural morphine infusion trial in a patient with failed back surgery syndrome. Pain Physician 2008; 11: 363-367.
98. Ruan X, Liu H, Couch JP, Wang F, Chiravuri S,. Recurrent cellulitis associated with long-term intrathecal opioid infusion therapy: a case report and review of the literature. Pain Med 2010; 11: 972-976.
99. Duarte RV, Raphael JH, Southall JL, Baker C, Hanu-Cernat D,. Intrathecal inflammatory masses: is the yearly opioid dose increase an early indicator. Neuromodulation 2010; 13: 109-113.
100. Jourdain V, Cantin L, Prud'Homme M, Fournier-Gosselin M,. Intrathecal morphine therapy-related granulomas: faster to grow than thought. Neuromodulation 2009; 12: 164-168.
101. De Andrés J, Palmisani S, Villanueva Pérez VL, Asensio J, Lõpez-Alarcõn MD,. Can an intrathecal, catheter-tip-associated inflammatory mass reoccur? Clin J Pain 2010; 26: 631-634.
102. Hoederath P, Gautschi OP, Land M, Hildebrandt G, Fournier JY,. Formation of two consecutive intrathecal catheter tip granulomas within nine months. Cen Eur Neurosurg 2010; 71: 39-42.
103. Sloan P, Grider J,. Rapidly escalating intrathecal opioid dosing for cancer pain: a case report of catheter malposition not hyperalgesia. J Pain Symptom Manage 2010; 39: 446-447.
104. Vadera S, Harrop JS, Sharan AD,. Intrathecal granuloma and intramedullary abscess associated with an intrathecal morphine pump. Neuromodulation 2007; 10: 6-11.
105. Webb DM, Schneider JR, Lober RM, Vender JR,. Granulomatous conduit for intrathecal infusion of morphine and bupivacaine. Reg Anesth Pain Med 2001; 36: 195-197.
106. Abejõn D, del Saz JM, Ley L, Sanchez MR, del Pozo C,. [Spinal granuloma in a patient receiving a spinal infusion of morphine and clonidine][Article in Spanish]. Rev Esp Anestesiol Reanim 2009; 56: 380-384.
107. Williams BS, Wong D, Amin S,. Case scenario: self-extraction of intrathecal pump medication with a concomitant intrathecal granulomatous mass. Anesthesiology 2011; 114: 424-430.
108. Jhas S, Tuli S,. Intrathecal catheter-tip inflammatory masses: an intraparenchymal granuloma. J Neurosurg Spine 2008; 9: 196-199.
109. Leong S-K, Laing B, Saines N,. Magnetic resonance imaging (MRI) and computed tomography (CT) findings in intrathecal catheter granuloma: report of two cases. Eur J Radiol Extra 2010; 74: e17-e21.
110. Magill ST, Wang P, Eller JL, Burchiel KJ,. Differentiating intrathecal catheter tip granulomas from normal magnetic resonance image distortion caused by metallic catheter tips. Neurosurgery 2008; 62: 242-248.
111. Radhakrishnan L, Duarte R, Mutagi H, Kapur S, Raphael J,. Opiate tolerance in long-term intrathecal analgesia: 350 [abstract]. Reg Anesth Pain Med 2008; 33: e20.
112. Yaksh TL, Onofrio BM,. Retrospective consideration of the doses of morphine given intrathecally by chronic infusion of 163 patients by 19 physicians. Pain 1987; 31: 211-223.
113. Ramsey CN, Owen RD, Witt WO, Grider JS,. Intrathecal granuloma in a patient receiving high dose hydromorphone. Pain Physician 2008; 11: 369-373.
114. Medel R, Pouratian N, Elias WJ,. Catheter-tip mass mimicking a spinal epidural hematoma. J Neurosurg Spine 2010; 12: 66-71.
115. Gupta A, Martindale T, Christo PJ,. Intrathecal catheter granuloma associated with continuous sufentanil infusion. Pain Med 2010; 11: 847-852.
116. Rizzo CC, Luretti GR, Mattos AL,. The combination of methadone and dexamethasone for cancer pain. Eur J Pain 2009; 13 (Suppl. 1): S258.
117. Yaksh TL, Tozier N, Horais KA, et al,. Toxicology profile of N-methyl-D-aspartate antagonists delivered by intrathecal infusion in the canine model. Anesthesiology 2008; 108: 938-949.
118. Oztürk E, Beyazova M, Kaya K, Meray J, Zinnuroglu M, Tarhan B,. Perineural meperidine blocks nerve conduction in a dose-related manner: a randomized double-blind study. Acta Anaesthesiol Scand 2009; 53: 783-787.
119. Vranken JH, van der Vegt MH, van Kan HJ, Kruis MR,. Plasma concentrations of meperidine and normeperidine following continuous intrathecal meperidine in patients with neuropathic cancer pain. Acta Anaesthesiol Scand 2005; 49: 665-670.
120. De Andrés J, Tatay Vivõ J, Palmisani S, Villanueva Pérez VL, Minguez A,. Intrathecal granuloma formation in a patient receiving long-term spinal infusion of tramadol. Pain Med 2010; 11: 1059-1062.
121. Feng X, Zhang F, Dong R, et al,. Intrathecal administration of clonidine attenuates spinal neuroimmune activation in a rat model of neuropathic pain with existing hyperalgesia. Eur J Pharmacol 2009; 614: 38-43.
122. Guevara-Lõpez U, Aldrete JA, Covarrubias-Gõmez A, Hernández-Pando RE, Lõpez-Muñoz FJ,. Absence of histological changes after the administration of a continuous intrathecal clonidine in Wistar rats. Pain Pract 2009; 9: 122-129.
123. Martin TJ, Kim SA, Buechler NL, Porreca F, Eisenach JC,. Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. Anesthesiology 2007; 106: 312-322.
124. Roh DH, Kim HW, Yoon SY, et al,. Intrathecal clonidine suppresses phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit in spinal dorsal horn neurons of rats with neuropathic pain. Anesth Analg 2008; 107: 693-700.
125. Ando Y, Hojo M, Kanaide M, et al,. S(+)-Ketamine suppresses desensitization of gamma-aminobutyric acid type B receptor-mediated signaling by inhibition of the interaction of gamma-aminobutyric acid type B receptors with G protein-coupled receptor kinase 4 or 5. Anesthesiology 2011; 114: 401-411.
126. Boettger MK, Weber K, Gajda M, Bräuer R, Schaible HG,. Spinally applied ketamine or morphine attenuate peripheral inflammation and hyperalgesia in acute and chronic phases of experimental arthritis. Brain Behav Immun 2010; 24: 474-485.
127. Infante C, Diaz M, Hernández A, Constandil L, Pelissier T,. Expression of nitric oxide synthase isoforms in the dorsal horn of monoarthritic rats: effects of competitive and uncompetitive N-methyl-D-aspartate antagonists. Arthritis Res Ther 2007; 9: R53.
128. Mei X, Wang W, Wang W, et al,. Inhibiting astrocytic activation: a novel analgesic mechanism of ketamine at the spinal level? J Neurochem 2009; 109: 1691-1700.
129. Mei XP, Zhang H, Wang W, et al,. Inhibition of spinal astrocytic c-Jun N-terminal kinase (JNK) activation correlates with the analgesic effects of ketamine in neuropathic pain. J Neuroinflammation 2011; 8: 6.
130. Walker SM, Westin BD, Deumens R, Grafe M, Yaksh TL,. Effects of intrathecal ketamine in the neonatal rat: evaluation of apoptosis and long-term functional outcome. Anesthesiology 2010; 113: 147-159.
131. Loram LC, Harrison JA, Sloane EM, et al,. Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. J Neurosci 2009; 29: 14015-14025.
132. Kuroiwa M, Kitano Y, Takasuna K, Manabe S, Saito T,. Muscle relaxant and neurotoxic activities of intrathecal baclofen in rats. Pharmacol Res 2009; 60: 392-396.
133. Lin CF, Tsaur ML, Lin CS, Chen CC, Huang YJ, Cheng JK,. Intrathecal gabapentin does not act as a hyperpolarization-activated cyclic nucleotide-gated channel activator in the rat formalin test. Eur J Anaesthesiol 2009; 26: 821-824.
134. Narita M, Nakajima M, Miyoshi K, et al,. Role of spinal voltage-dependent calcium channel alpha 2 delta-1 subunit in the expression of a neuropathic pain-like state in mice. Life Sci 2007; 80: 2015-2024.
135. Takasusuki T, Yaksh TL,. The effects of intrathecal and systemic gabapentin on spinal substance p release. Anesth Analg 2011; 112: 971-976.
136. Takeuchi Y, Takasu K, Honda M, Ono H, Tanabe M,. Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury. Eur J Pharmacol 2007; 556: 69-74.
137. Van Elstraete AC, Sitbon P, Mazoit JX, Benhamou D,. Gabapentin prevents delayed and long-lasting hyperalgesia induced by fentanyl in rats. Anesthesiology 2008; 108: 484-494.
138. Eisenach JC, Curry R, Tong C, Houle TT, Yaksh TL,. Effects of intrathecal ketorolac on human experimental pain. Anesthesiology 2010; 112: 1216-1224.
139. Horvath G, Kekesi G, Tuboly G, Benedek G,. Antinociceptive interactions of triple and quadruple combinations of endogenous ligands at the spinal level. Brain Res 2007; 1155: 42-48.
140. Lizarraga I, Chambers JP, Johnson CB,. Prevention of N-methyl-D- aspartate-induced mechanical nociception by intrathecal administration of ketoprofen and ketamine in sheep. Anesth Analg 2008; 107: 2061-2067.
141. Mei XP, Wang W, Zhu C, et al,. Combining ketamine with astrocytic inhibitor as a potential analgesic strategy for neuropathic pain. Ketamine, astrocytic inhibitor and pain. Mol Pain 2010; 6: 50.
142. Ortega-Varela LF, Herrera JE, Caram-Salas NL, Rocha-González HI, Granados-Soto V,. Isobolographic analyses of the gabapentin-metamizol combination after local peripheral, intrathecal and oral administration in the rat. Pharmacology 2007; 79: 214-222.
143. Park JY, Jun IG,. The interaction of gabapentin and N6-(2- phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on mechanical allodynia in rats with a spinal nerve ligation. J Korean Med Sci 2008; 23: 678-684.
144. Pelissier T, Infante C, Constandil L, Espinosa J, Lapeyra CD, Hernández A,. Antinociceptive effect and interaction of uncompetitive and competitive NMDA receptor antagonists upon capsaicin and paw pressure testing in normal and monoarthritic rats. Pain 2008; 134: 113-127.
145. Yamama Y, Nishikawa K, Funao T, Mori T, Asada A,. Intrathecal gabapentin and clonidine synergistically inhibit allodynia in spinal nerve-ligated rats. Life Sci 2010; 87: 565-571.
146. Schroeder CI, Doering CJ, Zamponi GW, Lewis RJ,. N-type calcium channel blockers: novel therapeutics for the treatment of pain. Med Chem 2006; 2: 535-543.
147. Yamamoto T, Takahara A,. Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem 2009; 9: 377-395.
148. Skov MJ, Beck JC, de Kater AW, Shopp GM,. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Int J Toxicol 2007; 26: 411-421.
149. Wallace MS, Rauck R, Fisher R, Charapata SG, Ellis D, Dissanayake S,. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg 2008; 106: 628-637. table of contents.
150. Webster LR, Fisher R, Charapata S, Wallace MS,. Long-term intrathecal ziconotide for chronic pain: an open-label study. J Pain Symptom Manage 2009; 37: 363-372.
151. Kress HG, Ver Donck A, Kleinmann B, et al,. Ziconotide for the management of severe, chronic pain: interim data from the PRIME registry [abstract]. Reg Anesth Pain Med 2010; 35: E122.
152. Vogt E, Macrea LM, Schleinzer W,. Treatment of neuropathic pain with intrathecal ziconotide [abstract]. Eur J Pain Suppl 2010; 4: 122.
153. Kapural L, Lokey K, Leong MS, et al,. Intrathecal ziconotide for complex regional pain syndrome: seven case reports. Pain Pract 2009; 9: 296-303.
154. McDowell GC, Mitchell JW, Moore TD,. The use of intrathecal ziconotide to manage refractory malignant pain: five case studies [abstract]. J Clin Oncol 2009; 27 (Suppl. 1): abstr e20737.
155. Munson ML, Saharan V, George S,. Analysis of adverse events related to ziconotide intrathecal administration: utilization of the FDA AERS database. Pharmacoepidemiology Drug Safety 2009; 18 (Suppl. 1): S84.
156. Rasche D, Klase D, Tronnier V,. Single-centre clinical experience using ziconotide for the treatment of chronic neuropathic pain syndromes [abstract]. Eur J Pain 2009; 13 (Suppl. 1): S259-S260.
157. Wallace MS, Kosek PS, Staats P, Fisher R, Schultz DM, Leong M,. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 2008; 9: 271-281.
158. Deer TR, Kim C, Bowman R, Tolentino D, Stewart C, Tolentino W,. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study. Pain Physician 2009; 12: E291-E296.
159. Saulino M, Burton AW, Danyo DA, Frost S, Glanzer J, Solanki DR,. Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports. Eur J Phys Rehabil Med 2009; 45: 61-67.
160. Saulino M,. Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report. Spinal Cord 2007; 45: 749-752.
161. Ruíz Ortiz S, Gálvez R, Romero Cotelo J, Lõpez Tapia F, Martín De Rosales J, Romero Rodríguez Y,. Intrathecal ziconotide combined with two other drugs in two cases of refractory spinal cord injury pain [abstract]. Eur J Pain 2009; 13 (Suppl. 1): S259-S260.
162. Shah A, Akbik H,. A side effect profile comparison of single shot
163. Raffaeli W, Sarti D, Russo R, Marneli S,. Detoxification from intrathecal morphine, for the shift from morphine to ziconotide intrathecal therapy: Italian register [abstract]. Eur J Pain 2009; 13 (Suppl.): S51.
164. Baker L, Balls J, Regnard C, Pridie A,. Cervical intrathecal analgesia for head and neck/upper limb cancer pain: six case reports. Palliat Med 2007; 21: 543-545.
165. Goucke CR, Dusci LJ, Van Leeuwen S, Fairclough D, Ilett KF,. Stability and tolerability of high concentrations of intrathecal bupivacaine and opioid mixtures in chronic noncancer pain: an open-label pilot study. Pain Med 2010; 11: 1612-1618.
166. Mironer E, Haasis J, Chapple I, Brown C, Satterthwaite JR,. Efficacy and safety of intrathecal opioid/bupivacaine mixture in chronic nonmalignant pain: a double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians (NFIPC). Neuromodulation: Technology at the Neural Interface 2002; 5: 208-213.
167. Zhong Z, Qulian G, Yuan Z, Wangyuan Z, Zhihua S,. Repeated intrathecal administration of ropivacaine causes neurotoxicity in rats. Anaesth Intensive Care 2009; 37: 929-936.
168. Yang SH, Guo QL, Wang YC,. Alterations of myelin basic protein concentration in the plasma and ultrastructure in the spinal cord after continuous intrathecal ropivacaine injection in rats [Article in Chinese]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008; 33: 527-532.
169. Zhang Z, Hu Y, Zhao Y, Chen C, Guo Q, Sun Z,. Behavioral and ultrastructural changes of intrathecal administered ropivacaine in spinal cord of rats [Article in Chinese]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009; 34: 362-368.
170. Malinovsky JM, Charles F, Baudrimont M, et al,. Intrathecal ropivacaine in rabbits: pharmacodynamic and neurotoxicologic study. Anesthesiology 2002; 97: 429-435.
171. Yamashita A, Matsumoto M, Matsumoto S, Itoh M, Kawai K, Sakabe T,. A comparison of the neurotoxic effects on the spinal cord of tetracaine, lidocaine, bupivacaine, and ropivacaine administered intrathecally in rabbits. Anesth Analg 2003; 97: 512-519.
172. Whitlock EL, Brenner MJ, Fox IK, Moradzadeh A, Hunter DA, Mackinnon SE,. Ropivacaine-induced peripheral nerve injection injury in the rodent model. Anesth Analg 2010; 111: 214-220.
173. Michalek-Sauberer A, Kozek-Langenecker SA, Heinzl H, Deusch E, Chiari A,. Median effective local anesthetic doses of plain bupivacaine and ropivacaine for spinal anesthesia administered via a spinal catheter for brachytherapy of the lower abdomen. Reg Anesth Pain Med 2008; 33: 4-9.
174. Geng ZY, Wang DX, Wu XM,. Minimum effective local anesthetic dose of intrathecal hyperbaric ropivacaine and bupivacaine for cesarean section. Chin Med J (Engl) 2011; 124: 509-513.
175. Lee YY, Ngan Kee WD, Chang HK, So CL, Gin T,. Spinal ropivacaine for lower limb surgery: a dose response study. Anesth Analg 2007; 105: 520-523.
176. Ortner CM, Posch M, Roessler B, et al,. On the ropivacaine-reducing effect of low-dose sufentanil in intrathecal labor analgesia. Acta Anaesthesiol Scand 2010; 54: 1000-1006.
177. Parpaglioni R, Baldassani B, Barbati G, Celleno D,. Adding sufentanil to levobupivacaine or ropivacaine intrathecal anaesthesia affects the minimum local anaesthetic dose required. Acta Anaesthesiol Scand 2009; 53: 1214-1220.
178. Levin A, Datta S, Camann WR,. Intrathecal ropivacaine for labor analgesia: a comparison with bupivacaine. Anesth Analg 1998; 87: 624-627.
179. Farid IS, Heiner EJ,. Intrathecal local anesthetic infusion as a treatment for complex regional pain syndrome in a child. Anesth Analg 2007; 104: 1078-1080. tables of contents.
180. Schoeniger-Skinner DK, Ledeboer A, Frank MG, et al,. Interleukin-6 mediates low-threshold mechanical allodynia induced by intrathecal HIV-1 envelope glycoprotein gp120. Brain Behav Immun 2006; 21: 660-667.
181. Ledeboer A, Jekich BM, Sloane EM, et al,. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun 2007; 21: 686-698.
182. Yaksh TL, Rathbun M, Jage J, Mirzai TH, Grafe M, Hiles RA,. Pharmacology and toxicology of chronicaly infused epidural clonidine HCl in dogs. Fundam Appl Toxicol 1994; 23: 319-335.
183. Bevacqua BK, Fattouh M, Backonja M,. Depression, night terrors, and insomnia associated with long-term intrathecal clonidine therapy. Pain Pract 2007; 7: 36-38.
184. Brummett CM, Norat MA, Palmisano JM, Lydic R,. Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat. Anesthesiology 2008; 109: 502-511.
185. Konakci S, Adanir T, Yilmaz G, Rezanko T,. The efficacy and neurotoxicity of dexmedetomidine administered via the epidural route. Eur J Anaesthesiol 2008; 25: 403-409.
186. Ugur F, Gulcu N, Boyaci A,. Intrathecal infusion therapy with dexmedetomidine-supplemented morphine in cancer pain. Acta Anaesthesiol Scand 2007; 51: 388.
187. Yaksh TL, Hua XY, Kalcheva J, Nozaki-Taguchi N, Marsala M,. The spinal biology in humans and animals of pain states generated by persistent small afferent input. Proc Natl Acad Sci U S A 1999; 96: 7680-7686.
188. Wilson JA, Nimmo AF, Fleetwood-Walker SM, Colvin LA,. A randomised double blind trial of the effect of pre-emptive epidural ketamine on persistent pain after lower limb amputation. Pain 2008; 135: 108-118.
189. Sato C, Okabe T, Nakanishi K, Sakamoto A,. A case of cancer pain management by long-term intrathecal PCA. J Nihon Med Sch 2010; 77: 333-337.
190. Zylka MJ, Sowa NA, Taylor-Blake B, et al,. Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 2008; 60: 111-122.
191. Tsuda M, Toyomitsu E, Komatsu T, et al,. Fibronectin/integrin system is involved in P2X(4) receptor upregulation in the spinal cord and neuropathic pain after nerve injury. Glia 2008; 56: 579-585.
192. Nakagawa T, Wakamatsu K, Maeda S, Shirakawa H, Kaneko S,. Differential contribution of spinal mitogen-activated protein kinases to the phase of long-lasting allodynia evoked by intrathecal administration of ATP in rats. Biol Pharm Bull 2008; 31: 1164-1168.
193. Nakagawa T, Wakamatsu K, Zhang N, et al,. Intrathecal administration of ATP produces long-lasting allodynia in rats: differential mechanisms in the phase of the induction and maintenance. Neuroscience 2007; 147: 445-455.
194. Chiari A, Yaksh TL, Myers RR, et al,. Preclinical toxicity screening of intrathecal adenosine in rats and dogs. Anesthesiology 1999; 91: 824-832.
195. Munro G, Ahring PK, Mirza NR,. Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci 2009; 30: 453-459.
196. Zeilhofer HU, Witschi R, Hösl K,. Subtype-selective GABAA receptor mimetics-novel antihyperalgesic agents? J Mol Med 2009; 87: 465-469.
197. Sabbe MB, Grafe MR, Pfeifer BL, Mirzai TH, Yaksh TL,. Toxicology of baclofen continuously infused into the spinal intrathecal space of the dog. Neurotoxicology 1993; 14: 397-410.
198. Ward A, Hayden S, Dexter M, Scheinberg A,. Continuous intrathecal baclofen for children with spasticity and/or dystonia: goal attainment and complications associated with treatment. J Paediatr Child Health 2009; 45: 720-726.
199. Borowski A, Littleton AG, Borkhuu B, et al,. Complications of intrathecal baclofen pump therapy in pediatric patients. J Pediatr Orthop 2010; 30: 76-81.
200. Koulousakis A, Kuchta J,. Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study. Acta Neurochir Suppl 2007; 97 (pt 1): 181-184.
201. Ucar T, Kazan S, Turgut U, Samanci NK,. Outcomes of intrathecal baclofen (ITB) therapy in spasticity. Turk Neurosurg 2011; 21: 59-65.
202. Saval A, Chiodo AE,. Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin. J Spinal Cord Med 2010; 33: 16-21.
203. Santamato A, Panza F, Ranieri M, et al,. Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: a case report. J Rehabil Med 2010; 42: 891-894.
204. Sivakumar G, Yap Y, Tsegaye M, Vloeberghs M,. Intrathecal baclofen therapy for spasticity of cerebral origin-does the position of the intrathecal catheter matter? Childs Nerv Syst 2010; 26: 1097-1102.
205. Saval A, Chiodo AE,. Effect of intrathecal baclofen concentration on spasticity control: case series. J Spinal Cord Med 2008; 31: 394-397.
206. McClelland S 3rd, Bethoux FA, Boulis NM, et al,. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve 2008; 37: 396-398.
207. Ramstad K, Jahnsen R, Lofterod B, Skjeldal OH,. Continuous intrathecal baclofen therapy in children with cerebral palsy-when does improvement emerge? Acta Paediatr 2010; 99: 1661-1665.
208. Brochard S, Remy-Neris O, Filipetti P, Bussel B,. Intrathecal baclofen infusion for ambulant children with cerebral palsy. Pediatr Neurol 2009; 40: 265-270.
209. Hoving MA, van Raak EP, Spincemaille GH, Palmans LJ, Becher JG, Vles JS,. Efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a randomised controlled trial. Eur J Paediatr Neurol 2009; 13: 240-246.
210. Hoving MA, van Raak EP, Spincemaille GH, et al,. Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy. Eur J Paediatr Neurol 2009; 13: 247-256.
211. Hoving MA, van Raak EP, Spincemaille GH, Palmans LJ, Sleypen FA, Vles JS,. Intrathecal baclofen in children with spastic cerebral palsy: a double-blind, randomized, placebo-controlled, dose-finding study. Dev Med Child Neurol 2007; 49: 654-659.
212. Krach LE, Kriel RL, Day SM, Strauss DJ,. Survival of individuals with cerebral palsy receiving continuous intrathecal baclofen treatment: a matched-cohort study. Dev Med Child Neurol 2010; 52: 672-676.
213. Krach LE, Kriel RL, Nugent AC,. Complex dosing schedules for continuous intrathecal baclofen infusion. Pediatr Neurol 2007; 37: 354-359.
214. Borowski A, Shah SA, Littleton AG, Dabney KW, Miller F,. Baclofen pump implantation and spinal fusion in children: techniques and complications. Spine 2008; 33: 1995-2000.
215. Matsuda R, Nishimura F, Hirabayashi H, et al,. Case report of intrathecal baclofen administration in a child with severe spasticity attributable to traumatic brain injury [in Japanese]. Brain Nerve 2009; 61: 313-315.
216. Francisco GE, Latorre JM, Ivanhoe CB,. Intrathecal baclofen therapy for spastic hypertonia in chronic traumatic brain injury. Brain Inj 2007; 21: 335-338.
217. Bowden M, Stokic DS,. Clinical and neurophysiologic assessment of strength and spasticity during intrathecal baclofen titration in incomplete spinal cord injury: single-subject design. J Spinal Cord Med 2009; 32: 183-190.
218. D'Aleo G, Rifici C, Kofler M, Saltuari L, Bramanti P,. Favorable response to intrathecal, but not oral, baclofen of priapism in a patient with spinal cord injury. Spine (Phila Pa 1976) 2009; 34: E127-E129.
219. Maramattom BV,. Intrathecal baclofen pump implantation in a case of stiff person syndrome. Neurol India 2010; 58: 115-117.
220. Ho BL, Shih PY,. Successful intrathecal baclofen therapy for seronegative stiff-person syndrome: a case report. Acta Neurol Taiwan 2008; 17: 172-176.
221. Heetla HW, Staal MJ, Kliphuis C, van Laar T,. The incidence and management of tolerance in intrathecal baclofen therapy. Spinal Cord 2009; 47: 751-756.
222. Dones I, Broggi G,. A case of very long-term appearing drug tolerance to intrathecal baclofen. J Neurosurg Sci 2010; 54: 77-78.
223. Hansen CR, Gooch JL, Such-Neibar T,. Prolonged, severe intrathecal baclofen withdrawal syndrome: a case report. Arch Phys Med Rehabil 2007; 88: 1468-1471.
224. Salazar ML, Eiland LS,. Intrathecal baclofen withdrawal resembling serotonin syndrome in an adolescent boy with cerebral palsy. Pediatr Emerg Care 2008; 24: 691-693.
225. D'Aleo G, Cammaroto S, Rifici C, et al,. Hallucinations after abrupt withdrawal of oral and intrathecal baclofen. Funct Neurol 2007; 22: 81-88.
226. Ross JC, Cook AM, Stewart GL, Fahy BG,. Acute intrathecal baclofen withdrawal: a brief review of treatment options. Neurocrit Care 2011; 14: 103-108.
227. Fernandes P, Dolan L, Weinstein SL,. Intrathecal baclofen withdrawal syndrome following posterior spinal fusion for neuromuscular scoliosis: a case report. Iowa Orthop J 2008; 28: 77-80.
228. Duhon BS, MacDonald JD,. Infusion of intrathecal baclofen for acute withdrawal. Technical note. J Neurosurg 2007; 107: 878-880.
229. Dalton C, Keenan E, Stevenson V,. A novel cause of intrathecal baclofen overdosage: lessons to be learnt. Clin Rehabil 2008; 22: 188-190.
230. Burn SC, Zeller R, Drake JM,. Do baclofen pumps influence the development of scoliosis in children? J Neurosurg Pediatr 2010; 5: 195-199.
231. Ginsburg GM, Lauder AJ,. Progression of scoliosis in patients with spastic quadriplegia after the insertion of an intrathecal baclofen pump. Spine (Phila Pa 1976) 2007; 32: 2745-2750.
232. Shilt JS, Lai LP, Cabrera MN, Frino J, Smith BP,. The impact of intrathecal baclofen on the natural history of scoliosis in cerebral palsy. J Pediatr Orthop 2008; 28: 684-687.
233. Senaran H, Shah SA, Presedo A, Dabney KW, Glutting JW, Miller F,. The risk of progression of scoliosis in cerebral palsy patients after intrathecal baclofen therapy. Spine (Phila Pa 1976) 2007; 32: 2348-2354.
234. Herranz Gordo A, Villanueva Pérez V, Pérez Cervellõ A, Cerdá Olmedo G, Pallardõ Lõpez MA, De Andrés Ibáñez JA,. Continuous infusion of baclofen and an antibiotic for treating meningitis related to refilling of an intrathecal infusion pump reservoir [in Spanish]. Rev Esp Anestesiol Reanim 2008; 55: 43-46.
235. Peerdeman SM, de Groot V, Feller RE,. In situ treatment of an infected intrathecal baclofen pump implant with gentamicin-impregnated collagen fleece. J Neurosurg 2010; 112: 1308-1310.
236. Deer TR, Raso LJ, Garten TG,. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication. Pain Med 2007; 8: 259-262.
237. Deer TR, Raso LJ, Coffey RJ, Allen JW,. Intrathecal baclofen and catheter tip inflammatory mass lesions (granulomas): a reevaluation of case reports and imaging findings in light of experimental, clinicopathological, and radiological evidence. Pain Med 2008; 9: 391-395.
238. Munts AG, Voormolen JH, Marinus J, Delhaas EM, van Hilten JJ,. Postdural puncture headache in complex regional pain syndrome: a retrospective observational study. Pain Med 2009; 10: 1469-1475.
239. D'Aleo G, Rifici C, Kofler M, Sessa E, Saltuari L, Bramanti P,. Seizure after intrathecal baclofen bolus in a multiple sclerosis patient treated with oxcarbazepine. Neurol Sci 2011; 32: 293-295.
240. Castaño B, Benito J, Pires F, Ferreira S, Lopez R, Vidal J,. Delirium secondary to intrathecal baclofen. Spinal Cord 2009; 47: 477-480.
241. Grande LA, Loeser JD, Samii A,. Recurrent transient global amnesia with intrathecal baclofen. Anesth Analg 2008; 106: 1284-1287.
242. Dvorak EM, McGuire JR, Nelson ME,. Incidence and identification of intrathecal baclofen catheter malfunction. PM R 2010; 2: 751-756.
243. Khan AA, Birks-Agnew I, Bullock P, Rushton D,. Clinical outcome and complications of intrathecal baclofen pump in multiple sclerosis patients: a retrospective study. NeuroRehabilitation 2010; 27: 117-120.
244. Nakaji P, Consiglieri GD, Garrett MP, Bambakidis NC, Shetter AG,. Cranial migration of a baclofen pump catheter associated with subarachnoid hemorrhage: case report. Neurosurgery 2009; 65: E1212-E1213. discussion E1213.
245. Maugans TA,. Intracranial migration of a fractured intrathecal catheter from a baclofen pump system: case report and analysis of possible causes. Neurosurgery 2010; 66: 319-322.
246. Li TC, Chen MH, Huang JS, Chan JY, Liu YK, Chen MH,. Catheter migration after implantation of an intrathecal baclofen infusion pump for severe spasticity: a case report. Kaohsiung J Med Sci 2008; 24: 492-497.
247. Vanhauwaert DJ, Kalala JP, Baert E, et al,. Migration of pump for intrathecal drug delivery into the peritoneal cavity. Case report. Surg Neurol 2009; 71: 610-612. discussion 612.
248. Sorokin A, Annabi E, Yang WC, Kaplan R, Chen MH,. Subdural intrathecal catheter placement: experience with two cases. Pain Physician 2008; 11: 677-680.
249. Williams BS, Christo PJ,. Obstructed catheter connection pin discovered during intrathecal baclofen pump exchange. Clin J Pain 2009; 25: 256-259.
250. Carda S, Cazzaniga M, Taiana C, Pozzi R,. Intrathecal baclofen bolus complicated by deep vein thrombosis and pulmonary embolism. A case report. Eur J Phys Rehabil Med 2008; 44: 87-88.
251. Smit CA, Slim EJ,. Heart conduction problems in a tetraplegic patient caused by a single therapeutic dosage of Baclofen. Spinal Cord 2008; 46: 317-318.
252. Uchitel OD, Di Guilmi MN, Urbano FJ, Gonzalez-Inchauspe C,. Acute modulation of calcium currents and synaptic transmission by gabapentinoids. Channels (Austin) 2010; 4: 490-496.
253. Tuchman M, Barrett JA, Donevan S, Hedberg TG, Taylor CP,. Central sensitization and CA(V)α2Î́ ligands in chronic pain syndromes: pathologic processes and pharmacologic effect. J Pain 2010; 11: 1241-1249.
254. Rauck R,. Prospective IT gabapentin clinical study results. Presented at: 18th Napa Pain Conference; September 16-18, 2011; Napa, CA. 2011.
255. Svensson CI, Yaksh TL,. The spinal phospholipase-cyclooxygenase- prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 2002; 42: 553-583.
256. Harvey RJ, Depner UB, Wässle H, et al,. GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 2004; 304: 884-887.
257. Yaksh TL, Horais KA, Tozier N, et al,. Intrathecal ketorolac in dogs and rats. Toxicol Sci 2004; 80: 322-334.
258. Eisenach JC, Curry R, Rauck R, Pan P, Yaksh TL,. Role of spinal cyclooxygenase in human postoperative and chronic pain. Anesthesiology 2010; 112: 1225-1233.
259. Johansen MJ, Gradert TL, Satterfield WC, et al,. Safety of continous intrathecal midazolam infusion in the sheep model. Anesth Analg 2004; 98: 1528-1535.
260. Yaksh TL, Allen JW,. The use of intrathecal midazolam in humans: a case study of process. Anesth Analg 2004; 98: 1536-1545.
261. Dureja GP, Usmani H, Khan M, Tahseen M, Jamal A,. Efficacy of intrathecal midazolam with or without epidural methylprednisolone for management of post-herpetic neuralgia involving lumbosacral dermatomes. Pain Physician 2010; 13: 213-221.
262. Jones PG, Dunlop J,. Targeting the cholinergic system as a therapeutic strategy for the treatment of pain. Neuropharmacology 2007; 53: 197-206.
263. Bartolini A, Di Cesare Mannelli L, Ghelardini C,. Analgesic and antineuropathic drugs acting through central cholinergic mechanisms. Recent Pat Cardiovas Drug Discov 2011; 6: 119-140.
264. Yaksh TL, Grafe MR, Malkmus S, Rathbun ML, Eisenach JC,. Studies on the safety of chronically administered intrathecal neostigmine methylsulfate in rats and dogs. Anesthesiology 1995; 82: 412-427.
265. USP General. Chapter <797>. Pharmaceutical compounding: sterile preparations. Rockville, MD: USP Convention, 2004.
266. American Society of Health System Pharmacists. ASHP guideline on quality assurance for pharmacy-prepared sterile products. Am J Health Syst Pharm 2000; 57: 1150-1169.
267. Cooper JF, Thoma LA,. Screening extemporaneously compounded intraspinal injections with the bacterial endotoxins test. Am J Health Syst Pharm 2002; 59: 2426-2433.
268. Jones TF, Feler CA, Simmons BP, et al,. Neurologic complications including paralysis after a medication error involving implanted intrathecal catheters. Am J Med 2002; 112: 31-36.
269. Classen AM, Wimbish GH, Kupiec TC,. Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. J Pain Symptom Manage 2004; 28: 603-611.
270. Trissel LA, Xu QA, Pham L,. Physical and chemical stability of hydromorphone hydrochloride 1.5 and 80 mg/mL packaged in plastic syringes. Int J Pharm Compounding 2002; 6: 74-76.
271. Xu QA, Trissel LA, Pham L,. Physical and chemical stability of low and high concentrations of morphine sulfate with clonidine hydrochloride packed in plastic syringes. Int J Pharm Compounding 2002; 6: 66-69.
272. Godwin DA, Kim N-H, Zuniga R,. Stability of baclofen and clonidine hydrochloride admixture for intrathecal administration. Hosp Pharm 2001; 36: 950-954.
273. Bianchi F, Ginggen A, Tardy Y,. Stability and compatibility of drug mixtures in an implantable infusion system. Anaesthesia 2008; 63: 972-978.
274. Kress HG, Simpson KH, Marchettini P, Ver Donck A, Varrassi G,. Intrathecal therapy: what has changed with the introduction of ziconotide. Pain Pract 2009; 9: 338-347.
275. Rudich Z, Peng P, Dunn E, McCartney C,. Stability of clonidine in clonidine-hydromorphone mixture from implanted intrathecal infusion pumps in chronic pain patients. J Pain Symptom Manage 2004; 28: 599-602.
276. Balch RJ 3rd, Gofeld M,. Ultrasound-guided intrathecal baclofen trial: a retrospective case series examining a novel approach. PM R 2011; 3: 486-488.
277. Carrillo-Ruiz JD, Andrade P, Godinez-Cubillos N, et al,. Coupled obturator neurotomies and lidocaine intrathecal infusion to treat bilateral adductor spasticity and drug-refractory pain. J Neurosurg 2010; 113: 528-531.